X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9168) 9168
Newsletter (1289) 1289
Newspaper Article (71) 71
Magazine Article (11) 11
Dissertation (8) 8
Book Chapter (5) 5
Reference (4) 4
Transcript (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
deoxycholic acid (6362) 6362
animals (3489) 3489
humans (3285) 3285
male (2345) 2345
deoxycholic acid - pharmacology (1838) 1838
female (1562) 1562
rats (1448) 1448
research (1223) 1223
analysis (1180) 1180
biochemistry & molecular biology (1004) 1004
bile acids and salts - metabolism (987) 987
physiological aspects (932) 932
mice (927) 927
bile acids (912) 912
liver (881) 881
adult (811) 811
middle aged (794) 794
pharmacology & pharmacy (754) 754
bile (740) 740
kinetics (672) 672
cholesterol (658) 658
deoxycholic acid - analogs & derivatives (635) 635
gastroenterology & hepatology (630) 630
deoxycholic acid - metabolism (541) 541
liver - metabolism (503) 503
acids (488) 488
deoxycholic acid - chemistry (472) 472
deoxycholic-acid (471) 471
aged (466) 466
metabolism (465) 465
solubility (438) 438
hydrogen-ion concentration (423) 423
expression (415) 415
time factors (412) 412
bile acid (406) 406
bile-acids (400) 400
cancer (394) 394
ursodeoxycholic acid (392) 392
microbiology (381) 381
proteins (380) 380
physical fitness (363) 363
liver diseases (356) 356
health aspects (351) 351
protein binding (349) 349
bile acids and salts - pharmacology (347) 347
deoxycholic acid - administration & dosage (346) 346
medical research (341) 341
cholesterol - metabolism (339) 339
research article (336) 336
enzymes (329) 329
mass spectrometry (324) 324
apoptosis (321) 321
gene expression (319) 319
medicine, experimental (319) 319
drug combinations (313) 313
cholic acid (312) 312
lipids (308) 308
cell biology (304) 304
microbiota (303) 303
cholestasis (300) 300
rabbits (295) 295
universities and colleges (294) 294
ursodeoxycholic acid - therapeutic use (292) 292
chenodeoxycholic acid (289) 289
bile acids and salts - analysis (288) 288
in vitro techniques (288) 288
surgery (288) 288
care and treatment (287) 287
cytochrome p-450 (282) 282
dose-response relationship, drug (282) 282
micelles (281) 281
rats, sprague-dawley (276) 276
deoxycholic acid - therapeutic use (275) 275
liver - drug effects (273) 273
biophysics (270) 270
oncology (267) 267
metabolites (266) 266
glucose (262) 262
bile acids and salts - blood (261) 261
bile acids and salts - chemistry (261) 261
molecular weight (261) 261
obesity (256) 256
endocrinology & metabolism (255) 255
diet (254) 254
cattle (252) 252
activation (247) 247
gastroenterology and hepatology (247) 247
cells, cultured (239) 239
drugs (238) 238
in-vitro (238) 238
chemistry (237) 237
rodents (230) 230
chemistry, multidisciplinary (229) 229
rats, inbred strains (229) 229
cell line (228) 228
mice, inbred c57bl (226) 226
chenodeoxycholic acid - metabolism (221) 221
methods (221) 221
inflammation (220) 220
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10215) 10215
Japanese (186) 186
German (91) 91
Russian (69) 69
French (61) 61
Chinese (57) 57
Spanish (32) 32
Italian (28) 28
Korean (15) 15
Polish (8) 8
Portuguese (8) 8
Ukrainian (6) 6
Czech (3) 3
Dutch (2) 2
Serbian (2) 2
Bulgarian (1) 1
Danish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 6, pp. 1398 - 1404
[Display omitted] Bile acids (BAs) are major regulators of hepatic BA and lipid metabolism but their mechanisms of action in non-alcoholic fatty liver disease (NAFLD... 
Gastroenterology and Hepatology | 3-hydroxy-3-methylglutaryl-CoA reductase | Stearoyl-CoA desaturase | Non-alcoholic fatty liver disease | Lipogenesis | FGF19 | 3-hydroxy-3-methylglutaryl- CoA reductase | FXR | NONALCOHOLIC STEATOHEPATITIS | AGONISTS | NUCLEAR RECEPTOR | CHOLESTEROL-METABOLISM | TRANSPORT | FEEDBACK-REGULATION | LIVER | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | ADIPOSE-TISSUE | Ursodeoxycholic Acid - administration & dosage | Oleic Acid - metabolism | Bile Acids and Salts - biosynthesis | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Non-alcoholic Fatty Liver Disease - metabolism | Intra-Abdominal Fat - metabolism | Obesity, Morbid - drug therapy | Non-alcoholic Fatty Liver Disease - drug therapy | Ursodeoxycholic Acid - pharmacology | Stearoyl-CoA Desaturase - biosynthesis | Liver - drug effects | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Lipid Metabolism - drug effects | Intra-Abdominal Fat - drug effects | Obesity, Morbid - metabolism | Physiological aspects | Obesity | Ursodiol | Deoxycholic acid | Index Medicus | BAs, bile acids | nCEH, neutral cholesterol ester hydrolase | ApoB, apolipoprotein B | LDLR, low density lipoprotein receptor | FGF19, fibroblast growth factor 19 | VLDL, very low density lipoproteins | ABC, ATP-binding cassette | TGs, triglycerides | NAFLD, non-alcoholic fatty liver disease | OA, oleic acid | C4, 7α-hydroxy-4-cholesten-3-one | SHP, small heterodimer partner | SREBP1c, sterol regulatory element-binding protein-1c | CA, cholic acid | PA, palmitic acid | FATP1, fatty acid transport protein 1 | UDCA, ursodeoxycholic acid | FAs, fatty acides | HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase | vWAT, visceral white adipose tissue | SCD, stearoyl-Coa desaturase | CYP7A1, cholesterol 7α-hydroxylase | NASH, non-alcoholic steatohepatitis | FXR, farnesoid X receptor | CDCA, chenodeoxycholic acid | MA, myristic acid | FASN, fatty acid synthase | MTTP, microsomal triglyceride transfer protein | SA, stearic acid | NONALCOHOLIC | FATTY LIVER-DISEASE | Gastroenterology & Hepatology | Endokrinologi och diabetes | STEATOHEPATITIS | PLACEBO-CONTROLLED TRIAL | COA DESATURASE | Endocrinology and Diabetes
Journal Article
Journal of hepatology, ISSN 0168-8278, 2013, Volume 58, Issue 1, pp. 155 - 168
Summary Bile acid (BA) transporters are critical for maintenance of the enterohepatic BA circulation where BAs exert their multiple physiological functions including stimulation of bile flow, intestinal absorption... 
Gastroenterology and Hepatology | Gallstones | Liver cancer | Bile acids | Fatty liver disease | Cholestasis | Liver regeneration | RAT-LIVER | SALT EXPORT PUMP | GROWTH-FACTOR 19 | ORGANIC ANION TRANSPORTERS | 90-PERCENT PARTIAL-HEPATECTOMY | URSODEOXYCHOLIC ACID | PRIMARY BILIARY-CIRRHOSIS | FARNESOID-X-RECEPTOR | GASTROENTEROLOGY & HEPATOLOGY | PHOSPHOLIPID-ASSOCIATED CHOLELITHIASIS | FAMILIAL INTRAHEPATIC CHOLESTASIS | Animals | Carrier Proteins - metabolism | Cholestasis - metabolism | Membrane Glycoproteins - metabolism | Humans | Liver - metabolism | Bile Acids and Salts - metabolism | Liver Diseases - metabolism | Liver Regeneration - physiology | Receptors, Cytoplasmic and Nuclear - metabolism | Drug resistance in microorganisms | Corticosteroids | Glucagon | Calcifediol | Ursodiol | Deoxycholic acid | Epidermal growth factor | Vitamin D | Physiological aspects | Fibroblast growth factors | Alfacalcidol | IBABP (FABP6, ILBP), intestinal bile acid-binding protein, fatty acid-binding protein 6 | PFIC, progressive familial intrahepatic cholestasis | TNFα, tumor necrosis factor α | 3 (human) | SRC2, p160 steroid receptor coactivator | NAFLD, non-alcoholic fatty liver disease | BA, bile acid | bile acid receptor | 8, cholesterol efflux pump, ATP-binding cassette, subfamily G, member 5 | UDCA, ursodeoxycholic acid | LRH-1 (NR5A2), liver receptor homolog-1 | LCA, lithocholic acid | LXRα (NR1H3), liver X receptor alpha | PPARγ (NR1C3), peroxisome proliferator-activated receptor gamma | OSTαβ, organic solute transporter alpha | ABCG5 | AMPK, AMP activated protein kinase | NASH, non-alcoholic steatohepatitis | SHP (NR0B2), short heterodimer partner | OATP1A2 (SLCO1A2, OATP1, OATP-A, SLC21A3), solute carrier organic anion transporter family, member 1A2 | EGFR, epidermal growth factor receptor | IL6, interleukin 6 | TGR5, G protein-coupled bile acid receptor | PH, partial hepatectomy | AE2, anion exchanger 2 | PSC, primary sclerosing cholangitis | OATP1B1 (SLCO1B1, OATP2, OATP-C, SLC21A6), solute carrier organic anion transporter family, member 1B1 | RARα (NR1B1), retinoic acid receptor alpha | GLP-1, glucagon like peptide 1 | VDR (NR1I1), vitamin D receptor. Please note that for the convenience of better readability and clarity, abbreviations for transporters and nuclear receptors were capitalized throughout this article when symbols were identical for human and rodents | MRP2 (ABCC2), multidrug resistance-associated protein 2, ATP-binding cassette, subfamily C, member 2 | NTCP (SLC10A1), sodium | CAR (NR1I3), constitutive androstane receptor | taurocholate cotransporting polypeptide, solute carrier family 10, member 1 | PPARα (NR1C1), peroxisome proliferator-activated receptor alpha | Review | GR (NR3C1), glucocorticoid receptor | Bile acids, Cholestasis, Fatty liver disease, Gallstones, Liver regeneration, Liver cancer | 19, fibroblast growth factor 15 | Mdr2 | ICP, intrahepatic cholestasis of pregnancy | BRIC, benign recurrent intrahepatic cholestasis | OATP1B3 (SLCO1B3, OATP8, SLC21A8), solute carrier organic anion transporter family, member 1B3 | MRP3 (ABCC3), multidrug resistance-associated protein 3, ATP-binding cassette, subfamily C, member 3 | beta | MDR1 (ABCB1), p-glycoprotein, ATP-binding cassette, subfamily B, member 1 | norUDCA, norursodeoxycholic acid | 6-ECDCA, 6-ethylchenodeoxycholic acid | FXR (NR1H4), farnesoid X receptor | BCRP (ABCG2), breast cancer resistance protein, ATP-binding cassette, subfamily G, member 2 | HNF4α (NR2A1), hepatocyte nuclear factor 4 alpha | PBC, primary biliary cirrhosis | MDR3 (ABCB4), multidrug resistance protein 2 (rodents) | HNF1α, hepatocyte nuclear factor 1 alpha | NR, nuclear receptor | FGF15 | RXRα (NR2B1), retinoid X receptor alpha | PXR (NR1I2), pregnane X receptor | BSEP (ABCB11), bile salt export pump | HCC, hepatocellular carcinoma | MRP4 (ABCC4), multidrug resistance-associated protein 4, ATP-binding cassette, subfamily C, member 4 | TPN, total parenteral nutrition
Journal Article
The American journal of clinical nutrition, ISSN 1938-3207, 2019, Volume 110, Issue 2, pp. 305 - 315
Background: Direct comparisons between SFAs varying in chain length, specifically palmitic acid (16: 0) and stearic acid (18: 0... 
stearic acid | BLOOD-LIPIDS | CHOLESTEROL | lipoprotein | LINOLEIC-ACID | oleic acid | SATURATED FATTY-ACIDS | palmitic acid | coagulation | lipid | cardiometabolic risk factors | secondary bile acids | POSTPRANDIAL LIPEMIA | NUTRITION & DIETETICS | PLASMA-LIPIDS | inflammation | immune response | CORONARY RISK | RICH DIET | VII COAGULANT ACTIVITY | LIPOPROTEINS | Stearic Acids - administration & dosage | Hypercholesterolemia - diet therapy | Palmitic Acid - pharmacology | Oleic Acid - administration & dosage | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Bile Acids and Salts - chemistry | Palmitic Acid - administration & dosage | Bile Acids and Salts - metabolism | Cross-Over Studies | Inflammation - diet therapy | Oleic Acid - pharmacology | Feces - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aged | Stearic Acids - pharmacology | Lipoproteins (low density) | E protein | Coagulation | Washouts | Lymphocytes T | Hydrophobicity | Palmitic acid | Risk factors | Randomization | Lymphocytes | Intestine | Oleic acid | Stearic acid | Lipoproteins (high density) | Immune system | Carbohydrates | Fasting | Immune response | Health risks | Risk analysis | Low density lipoprotein | Cholesterol | Post-menopause | Deoxycholic acid | Acids | Diet | Bile | Cardiometabolic risk factors | Inflammation | Lipoprotein | Secondary bile acids | Lipid
Journal Article
Clinical gastroenterology and hepatology, ISSN 1542-3565, 2014, Volume 12, Issue 12, pp. 2085 - 2091.e1
Journal Article
Journal of lipid research, ISSN 1539-7262, 2017, Volume 58, Issue 6, pp. 1143 - 1152
Journal Article
Cell metabolism, ISSN 1550-4131, 2013, Volume 17, Issue 2, pp. 225 - 235
Bile acids are synthesized from cholesterol in the liver and further metabolized by the gut microbiota into secondary bile acids... 
ACTIVATION | DISRUPTION | STEROIDS | LIVER | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | FARNESOID-X-RECEPTOR | GERM-FREE | ABSORPTION | DIFFERENTIAL REGULATION | BINDING | CELL BIOLOGY | Organ Specificity - drug effects | Taurocholic Acid - metabolism | Fibroblast Growth Factors - genetics | Ileum - metabolism | Gene Expression Profiling | Fibroblast Growth Factors - metabolism | Organ Specificity - genetics | Ileum - drug effects | Metagenome - genetics | Absorption | Liver - drug effects | Taurocholic Acid - analogs & derivatives | Taurocholic Acid - pharmacology | Metagenome - drug effects | Liver - metabolism | Gastrointestinal Tract - microbiology | Bile Acids and Salts - metabolism | Gastrointestinal Tract - drug effects | Gene Expression Regulation - drug effects | Cholesterol 7-alpha-Hydroxylase - genetics | Animals | Cholesterol 7-alpha-Hydroxylase - metabolism | Models, Biological | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Feedback, Physiological - drug effects | Anti-Bacterial Agents - pharmacology | Mice | Receptors, Cytoplasmic and Nuclear - metabolism | Physiological aspects | Fibroblast growth factors | Universities and colleges | Cytochrome P-450 | Deoxycholic acid | Cell and Molecular Biology | Clinical Medicine | Klinisk medicin | Cell- och molekylärbiologi | Gastroenterology and Hepatology | Gastroenterologi
Journal Article
American journal of physiology: Gastrointestinal and liver physiology, ISSN 1522-1547, 2017, Volume 312, Issue 6, pp. G550 - G558
Journal Article